Electromed (ELMD) Competitors

Electromed (NYSE:ELMD) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk.

Which has more volatility and risk, ELMD or BVS?

Electromed has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Do institutionals & insiders believe in ELMD or BVS?

40.8% of Electromed shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 14.0% of Electromed shares are held by insiders. Comparatively, 32.9% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the media favor ELMD or BVS?

In the previous week, Bioventus had 4 more articles in the media than Electromed. MarketBeat recorded 6 mentions for Bioventus and 2 mentions for Electromed. Bioventus' average media sentiment score of 0.96 beat Electromed's score of 0.30 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Electromed	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ELMD or BVS more profitable?

Electromed has a net margin of 11.34% compared to Bioventus' net margin of -7.11%. Electromed's return on equity of 15.71% beat Bioventus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Bioventus	-7.11%	15.61%	4.01%

Which has preferable earnings and valuation, ELMD or BVS?

Electromed has higher earnings, but lower revenue than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$59.63M	3.46	$5.15M	$0.75	32.15
Bioventus	$573.28M	1.33	-$156.23M	-$0.51	-18.49

Does the MarketBeat Community believe in ELMD or BVS?

Bioventus received 10 more outperform votes than Electromed when rated by MarketBeat users. However, 91.30% of users gave Electromed an outperform vote while only 63.27% of users gave Bioventus an outperform vote.

Company	Underperform	Outperform
Electromed	Outperform Votes 21 91.30%	Underperform Votes 2 8.70%
Bioventus	Outperform Votes 31 63.27%	Underperform Votes 18 36.73%

Do analysts recommend ELMD or BVS?

Electromed currently has a consensus price target of $38.00, indicating a potential upside of 57.61%. Bioventus has a consensus price target of $15.00, indicating a potential upside of 59.07%. Given Bioventus' higher possible upside, analysts clearly believe Bioventus is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Electromed beats Bioventus on 10 of the 19 factors compared between the two stocks.